Xeos

What Xeos does

Xeos is a Belgian medical technology company founded in 2019 and headquartered in Ghent that has developed the AURA 10, the first intraoperative specimen PET-CT imaging system designed for use directly in the operating room. The AURA 10 combines high-resolution Positron Emission Tomography (PET) with X-ray Computed Tomography (CT) in a compact, mobile cart-based platform enabled by a proprietary 2-stage PET-CT detector configuration, delivering submillimeter spatial resolution and picomolar sensitivity within approximately 10 minutes of specimen excision. The companion AURAFlow software engine processes and displays images, supports DICOM/PACS integration, and underpins emerging deep learning capabilities for automated tumor segmentation.

The company targets surgical oncologists performing breast-conserving surgery, prostatectomies, and head and neck cancer resections, where the AURA 10 addresses the clinical problem of positive surgical margins — present in 12-30% of breast-conserving procedures — that currently require reoperations. Clinical validation comes primarily from the 148-patient BrIMA study published in JAMA Surgery, which reported success rate improvements from 83.3% to 95.2% for invasive ductal carcinoma margin assessment. Xeos monetizes the AURA 10 through direct enterprise sales of capital equipment to hospitals and academic medical centers, supplemented by multi-year service contracts, with sales cycles of 9-12+ months and a field-based sales organization across Europe and the United States.

Xeos holds CE marking under IVDR (March 2022), FDA 510(k) clearance (September 2023), and ISO 13485 certification, and operates in 8+ countries with a team of approximately 20 people. The company has raised €14 million as of January 2026 from Belgian healthcare technology investors to support commercial expansion, reference center buildout, and further clinical and health-economic evidence generation.

Name

Xeos

Legal name

XEOS

Website

https://xeos.care

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

Xeos is a Belgian medical technology company that developed the AURA 10, the first intraoperative specimen PET-CT imager for the operating room, serving surgical oncologists performing breast, prostate, and head and neck cancer resections at hospitals and academic medical centers across Europe and the United States.

Ownership category

akta.pro rank

Product category

Surgical Imaging Equipment / Intraoperative PET-CT Systems

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Irradiation Apparatus Manufacturing (334517)

SIC

Surgical & Medical Instruments & Apparatus (3841), X-Ray Apparatus & Tubes & Related Irradiation Apparatus (3844)

akta.pro primary industry

Intraoperative Imaging & Guidance (C-arms, O-arm, IOUS, fluorescence) (HLAHADAH)

Keywords

• Intraoperative specimen imaging
• PET-CT medical imaging
• Surgical oncology devices
• Margin assessment systems
• Molecular imaging equipment

Headquarters

HQ city

Gent

HQ country

Belgium

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Others

Revenue model

1. AURA 10 PET-CT System Sales: Sale of the AURA 10 specimen PET-CT imaging system as capital equipment to hospitals and healthcare institutions. Includes system installation, training, and ongoing support services.
2. Professional Services and Support: Implementation support, clinical training, and ongoing service contracts for installed systems. Associated with complex capital equipment sales cycles requiring significant customer engagement.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

Core offering

Xeos designs, manufactures, and sells the AURA 10, the first-ever PET-CT specimen imager for the operating room, which delivers high-resolution 3D molecular and anatomical imaging of resected surgical specimens within approximately 10 minutes of excision. The system is sold as capital equipment to hospitals and healthcare institutions, bundled with the AURAFlow visualization and reconstruction software, installation, clinical training, and multi-year service and support contracts for use in breast-conserving, prostate, and head-and-neck cancer surgery.

Product overview

Xeos offers a unified product portfolio centered on the AURA 10 PET-CT specimen imager for intraoperative molecular imaging. The core AURA 10 system combines PET and CT imaging in a compact, mobile platform for real-time specimen assessment during surgery. Supporting this is the AURAFlow visualization and reconstruction software, which processes and displays the imaging data. Together, these enable surgeons to assess resected tissue within minutes while the patient remains in the operating room.

Differentiator

Problem solved

Functional benefit

Brands

• AURA 10: The first-ever PET-CT specimen imager for the operating room, providing high-resolution three-dimensional imaging of excised surgical specimens directly in the OR.
• AURAFlow

Products and services

• AURA 10 PET-CT Specimen Imager The AURA 10 is the first intraoperative PET-CT specimen imager for the operating room, combining Positron Emission Tomography molecular sensitivity with submillimeter spatial resolution and high-resolution X-ray CT in a compact, mobile, cart-based system. It is sold as capital equipment to hospitals and cancer centers for use during breast-conserving, prostate, and head-and-neck cancer surgery, delivering specimen imaging within approximately 10 minutes of excision and integrating with PACS/DICOM hospital workflows.
• AURAFlow Visualization and Reconstruction Software AURAFlow is the visualization and reconstruction software that powers the AURA 10 system, providing clip verification images within 30 seconds, high-resolution CT reconstruction after 3 minutes, and PET images within 10 minutes. It includes zoom, annotation, measurement, slice scrolling, image rotation, window level adjustment, and a DICOM interface for hospital imaging workflows.

Quantifiable outcome

• Success rate improved from 83.3% to 95.2% for intraoperative margin assessment in invasive ductal carcinoma breast-conserving surgery
• +3 more outcomes

Named customers7 records

Segments4 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability2 records

Feature5 records

Partnerships

Two partnerships are on record, tiered core and minor.

• ARC (Sheba Medical Center Innovation Arm)coreGTM or Marketing Partner · 16 April 2026Xeos selected as one of six startups in ARC Landing Boston healthtech accelerator designed as a soft-landing platform for global healthtech companies entering the US market. Provides clinical environment access, regulatory support, strategic mentorship, and integration into ARC's global investment platforms. The six startups collectively raised $85 million.
• Southern ScientificminorChannel Partner/ Reseller/ DistributorPartner supporting eXcision study at University Hospitals Coventry & Warwickshire UK. Southern Scientific provides equipment and support services for the UK installation.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Perimeter Medical Imaging AI: Perimeter develops OCT-based intraoperative specimen imaging systems for breast cancer margin assessment. Directly competes with AURA 10 in the same clinical use case (intraoperative margin evaluation) and similar hospital customer base, using a different imaging modality.
• Lumicell: Lumicell develops intraoperative molecular imaging for tumor detection at the time of surgery, with breast cancer margin assessment as a lead indication. Closely comparable to Xeos in offering intraoperative molecular-level imaging to surgeons in the OR.
• Dune Medical Devices: Dune Medical develops the MarginProbe system using radiofrequency spectroscopy for intraoperative breast cancer margin assessment. Directly competes in the same clinical workflow (intraoperative margin evaluation during breast-conserving surgery).

Emerging players

• Sirius Medical: Sirius Medical offers the Pintuition magnetic seed localization system for breast tumor localization, addressing adjacent intraoperative surgical oncology workflow needs. Comparable target customer (breast surgeons) and OR workflow integration.
• Cairn Surgical: Cairn Surgical develops a breast cancer surgical guidance platform (Breast Cancer Locator) for intraoperative tumor localization. Comparable in serving breast cancer surgeons with intraoperative decision-support tools.

Broad incumbents

• Hologic: Hologic is a large women's health and surgical imaging company with broad mammography, ultrasound, and specimen radiography offerings that compete in breast cancer surgery workflows. Represents the established incumbent whose installed base and capital relationships Xeos must navigate.
• GE HealthCare: GE HealthCare is a dominant medical imaging OEM (PET-CT, CT, MRI, surgical imaging) that could enter the intraoperative specimen imaging space or acquire an existing player. Comparable as a broader imaging incumbent whose hospital relationships are essential for capital equipment sales.
• Siemens Healthineers: Siemens Healthineers is a global imaging equipment leader with extensive PET-CT and intraoperative imaging portfolios. Comparable as a broad imaging OEM with potential to disrupt or acquire the specimen PET-CT niche.
• Philips: Philips is a major medical imaging and surgical workflow vendor with PET-CT systems and intraoperative imaging products. Comparable as an incumbent whose scale and channel relationships could squeeze or acquire niche imaging players like Xeos.

Others

• Philips Spectral Diagnostics: Adjacent molecular imaging and AI-enabled radiology vendors that integrate with hospital PACS environments serve as ecosystem participants for Xeos's DICOM-enabled AURA 10 platform. Represents the broader imaging IT ecosystem in which AURA 10 must integrate.

Market position

Strengths4 records

Weaknesses2 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles16 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Xeos